METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

Post-LOE

metoprolol tartrate and hydrochlorothiazide

Viatris (2)

ANDAORALTABLET

Approved

Aug 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE (metoprolol tartrate and hydrochlorothiazide) by Viatris (2) is beta1-selective (cardioselective) adrenergic receptor blocker. Approved for hypertension, to lower blood pressure. First approved in 2004.

Drug data last refreshed 18h ago

Mechanism of Action

beta1-selective (cardioselective) adrenergic receptor blocker. This preferential effect is not absolute however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…

Pharmacologic Class:

Thiazide Diuretic

Indications (2)

hypertension

Worked on METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.